{"name":"Ionis Pharmaceuticals","slug":"ionis","ticker":"IONS","exchange":"NASDAQ","domain":"ionispharma.com","description":"Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.","hq":"Carlsbad, CA","founded":0,"employees":"1402","ceo":"Brett P. Monia","sector":"RNA Therapeutics","stockPrice":75.71,"stockChange":-1.89,"stockChangePercent":-2.44,"marketCap":"$12.5B","metrics":{"revenue":1058190016,"revenueGrowth":87,"grossMargin":10.9,"rdSpend":915619000,"netIncome":-381387000,"cash":1977063040,"dividendYield":0,"peRatio":-122.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Tegsedi patent cliff ($1.4B at risk)","drug":"Tegsedi","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Tegsrolin patent cliff ($500M at risk)","drug":"Tegsrolin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"cardiovascular","drugs":[{"name":"ISIS-GCGRRx","genericName":"ISIS-GCGRRx","slug":"isis-gcgrrx","indication":"Other","status":"phase_2"},{"name":"APOC-III-L-Rx","genericName":"APOC-III-L-Rx","slug":"apoc-iii-l-rx","indication":"Other","status":"phase_1"},{"name":"BIIB094","genericName":"BIIB094","slug":"biib094","indication":"Other","status":"phase_1"},{"name":"IONIS GHR-LRx","genericName":"IONIS GHR-LRx","slug":"ionis-ghr-lrx","indication":"Acromegaly","status":"phase_2"},{"name":"IONIS-DMPKRx","genericName":"IONIS-DMPKRx","slug":"ionis-dmpkrx","indication":"Other","status":"phase_1"},{"name":"ISIS 443139 10 mg","genericName":"ISIS 443139 10 mg","slug":"isis-443139-10-mg","indication":"Other","status":"phase_1"},{"name":"ISIS 443139 90 mg","genericName":"ISIS 443139 90 mg","slug":"isis-443139-90-mg","indication":"Other","status":"phase_1"},{"name":"ISIS apoC-III Rx","genericName":"ISIS apoC-III Rx","slug":"isis-apoc-iii-rx","indication":"Hypertriglyceridemia","status":"phase_2"},{"name":"ISIS-FXIRx Dose #2","genericName":"ISIS-FXIRx Dose #2","slug":"isis-fxirx-dose-2","indication":"Other","status":"phase_2"},{"name":"ISIS-GCCRRx","genericName":"ISIS-GCCRRx","slug":"isis-gccrrx","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ION363","genericName":"ION363","slug":"ion363","indication":"Hypertriglyceridemia in patients at high cardiovascular risk","status":"phase_3"},{"name":"ION582","genericName":"ION582","slug":"ion582","indication":"Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ISIS-FGFR4RX","genericName":"ISIS-FGFR4RX","slug":"isis-fgfr4rx","indication":"Solid tumors","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ISIS-PTP1BRx","genericName":"ISIS-PTP1BRx","slug":"isis-ptp1brx","indication":"Type 2 diabetes mellitus","status":"phase_2"}]}],"pipeline":[{"name":"ION363","genericName":"ION363","slug":"ion363","phase":"phase_3","mechanism":"ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.","indications":["Hypertriglyceridemia in patients at high cardiovascular risk"],"catalyst":""},{"name":"ISIS-FGFR4RX","genericName":"ISIS-FGFR4RX","slug":"isis-fgfr4rx","phase":"phase_2","mechanism":"Antisense oligonucleotide targeting fibroblast growth factor receptor 4","indications":["Solid tumors"],"catalyst":""},{"name":"ISIS-GCGRRx","genericName":"ISIS-GCGRRx","slug":"isis-gcgrrx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APOC-III-L-Rx","genericName":"APOC-III-L-Rx","slug":"apoc-iii-l-rx","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB094","genericName":"BIIB094","slug":"biib094","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ION582","genericName":"ION582","slug":"ion582","phase":"phase_3","mechanism":"ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels.","indications":["Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk"],"catalyst":""},{"name":"IONIS GHR-LRx","genericName":"IONIS GHR-LRx","slug":"ionis-ghr-lrx","phase":"phase_2","mechanism":"IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling.","indications":["Acromegaly"],"catalyst":""},{"name":"IONIS-DMPKRx","genericName":"IONIS-DMPKRx","slug":"ionis-dmpkrx","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS 443139 10 mg","genericName":"ISIS 443139 10 mg","slug":"isis-443139-10-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS 443139 90 mg","genericName":"ISIS 443139 90 mg","slug":"isis-443139-90-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS apoC-III Rx","genericName":"ISIS apoC-III Rx","slug":"isis-apoc-iii-rx","phase":"phase_2","mechanism":"Antisense oligonucleotide that targets apolipoprotein C-III","indications":["Hypertriglyceridemia"],"catalyst":""},{"name":"ISIS-FXIRx Dose #2","genericName":"ISIS-FXIRx Dose #2","slug":"isis-fxirx-dose-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS-GCCRRx","genericName":"ISIS-GCCRRx","slug":"isis-gccrrx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS-PTP1BRx","genericName":"ISIS-PTP1BRx","slug":"isis-ptp1brx","phase":"phase_2","mechanism":"ISIS-PTP1BRx is an antisense oligonucleotide that inhibits protein tyrosine phosphatase 1B (PTP1B) to improve insulin signaling and glucose metabolism.","indications":["Type 2 diabetes mellitus","Obesity"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ionis Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Ionis Pharmaceuticals Announces Collaboration with Biogen to Develop RNA Therapies for Neurodegenerative Diseases","summary":"Ionis Pharmaceuticals announced a collaboration with Biogen to develop RNA therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).","drugName":"","sentiment":"positive"},{"date":"2023-09-22","type":"regulatory","headline":"FDA Approves Tegsedi for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis)","summary":"The US FDA approved Tegsedi for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), a rare genetic disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNZkVCX0JVbVZiQzRKTGVuVTl5WXdBSHRRSnYzVWZ1d0lfdW1nd3ZLZXFyMGRDSFJ0R20yd21qcDlHQUpEOVVKeXEyLVZhR1JEaXFQXy1rUnU0ZjQxSXotMGJkTElMZ0dranBhT0ZlQnBVTmVjU2U0cDh5endsYXZLcGljYmp1VFlzT2Q5c0xHaUVBUkI0SU1IT2l2RUpMMkJSekNkUjFORDZXR1ZkamVhUlZzSTN1ZEU?oc=5","date":"2026-04-03","type":"pipeline","source":"Investing.com South Africa","summary":"Ionis Pharma director Klein sells $1.69m in IONS stock By Investing.com - Investing.com South Africa","headline":"Ionis Pharma director Klein sells $1.69m in IONS stock By Investing.com","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNTWYyTTdZQzF5VmdDQnpnOHVhdnFDaXhSbmZuSVJrMFJLR2JFOWNHYnR0VHItZGZ2NDNudVh0N0ZibHZsVHRXWmszT3RJOU90QTVhaDl0RkkwLXFTd250U0pUXzNYQlZCTXFWd0RKc0VDMDkydDVOR1d4Njd2UUFqbGZ0c2lqdjRhRDd2djM5dk9TTC01NndZZ3hab29ndFNlXzlSLXIxd1gzMkNSMmpDa2ZLTEVwZ0RVUjdHcw?oc=5","date":"2026-03-05","type":"pipeline","source":"Investing.com","summary":"Ionis Pharma EVP Devers sells $1.59 million in IONS stock - Investing.com","headline":"Ionis Pharma EVP Devers sells $1.59 million in IONS stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNaE5aM2M3c1pIM3JLY2s2SnJhTlg4eWVfMHRKa1M0RG45Um5vcUprYlRXVzhXQnRkM2d0UXZBLWtqZnBLc3VzQ1lTdXBkTVlodVNad1k5MjJRZFVjUjNXaXVaN0M4ODN6NHh0TEtEQzNPakdLa3JycjEzbXNleUpYSWZYdVJRU05wTHNPOFFsdmhUZVd6aVRlSzFyV1NtMENaOXFDdV95cUF0NnVHZGdGQVdNbHNfdmpPczlONXl3?oc=5","date":"2026-03-05","type":"pipeline","source":"Investing.com","summary":"Ionis Pharma EVP Bennett sells $6.74 million in IONS stock - Investing.com","headline":"Ionis Pharma EVP Bennett sells $6.74 million in IONS stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOMVM0WUtyYWxINnhTVHNGYkU4VHJ4M01JUWtPWXV0eDJQc3ZJX2NpbDM3ck5TOW9MUVNLNHRlQXZ4YTJaS2xPN2R0TzY3N1c3SnJJU3ljS2VEY0tKSFZGcUZYcU9ISjY1bzlGSmc2YVJPU0plTFVCY3VvUHJsU0poN2lDOE4tQV82MW1uRUR2NzYtZ2NHdHVnTEZ5cmFtNzJpaEd2R1dibXhJdV9sYXUyRFFFMW9vbTJ2NlJyTGFUaw?oc=5","date":"2026-02-17","type":"regulatory","source":"AD HOC NEWS","summary":"Ionis Pharmaceuticals: After the FDA Win, Is More Upside Left for IONS? - AD HOC NEWS","headline":"Ionis Pharmaceuticals: After the FDA Win, Is More Upside Left for IONS?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOajduWlJfNFRvLUFEQU10SGhreU5QRXhqdVBmWHJxVWluR3Y4T2tPRk9faWl5T0xnaUxFcEdYcmxEN1BSQ2ZhY1VQMGtvT3YxMHRHWk93UGx4V0U0ZE1WS3F5TVpGUmpmblNyRVlyM2tfWnBidnZraUNyT3lQYlNkQVdKX2xlbjZmTGtrbmNtNGg0V3l0azY1Nzh3MDhpSnJoYWlmR0JEc054blM3M3NlRjRHR3d1QW9tZnFFNm1ETQ?oc=5","date":"2025-09-23","type":"trial","source":"Stocktwits","summary":"Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits","headline":"Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9nYXc3elUyb0VHeXRNelpSU1lMM2YwOG5QX1pyZ0lMVDZ6TGdlUjdMaFl5YXNWd2FVU2d4LWRjc25ydVVkdGxocWFFT2d6US13TlllZHJGcEc2X1FxdVFGRWVtaWkwNk1lRkJQYy1GRS0zVEJqdHRIalFIeHlnZw?oc=5","date":"2025-09-04","type":"pipeline","source":"Yahoo Finance","summary":"Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen - Yahoo Finance","headline":"Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOZDlEZGxnZ3JzU0xESWdZSnQ4Q1J1RjZaYjNaNkNnX0thVTVYZmZHbDZZVDVvNnE0Q21jYlNyWUtyRGp0Zk45U2E5Snd4d0diZFRxWmhyMEZ2d0dCYlNJUlBCWTRsOGRac001X3Z4LXY2azFkSDIxQktOVU00YjNwLW9R?oc=5","date":"2025-09-03","type":"pipeline","source":"Yahoo Finance","summary":"Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results - Yahoo Finance","headline":"Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPbjRZajJtYzRTeTFUQmpwSl9UeFlPU2JnUVR3VEtxUlhuYXJoVUZLQ19xV0tlSWZXVm5PWXBVeDJyMzlrSVU0bEhuMU9TMmNZOGU3RUhLYWhGaEtmQU9SdXA0NkpYNXNER3NiUjlJYzYwUWlXZHFiOU1rU2dmS3hPcjdqWTJLd2ZtZTZMSDlJWUhJNFJxR0FyR3hlTWYyczBzcHhCS25uOEFKajhPNEVndHYwdU4wbzQ?oc=5","date":"2025-08-26","type":"regulatory","source":"Seeking Alpha","summary":"Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma (NASDAQ:IONS) - Seeking Alpha","headline":"Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma (NASDAQ:IONS)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOQVJCcVFuTGhkUjRXQll0akhRWnB0d19JZ1ZTQU1ONnJUaGNOT1ZvMGVHVGh0MGxRMXhzd2lyMlBLVm93Z1ExcFlxZU1JSjhVQm1GNWJ1NEU1TmhrdjF1YWRKYWplTnFhT01PWllQMG9BVlJTamxuajBQSFpvcG8xMWVJeGtkenczRGhvQXVhc1RFLTVndEhJa0hLT0xfdEJfVDhIMlh0N1FsS0VJN295MWFjTXdobjg?oc=5","date":"2025-08-22","type":"pipeline","source":"MedCity News","summary":"In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug - MedCity News","headline":"In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-01","type":"pipeline","source":"simplywall.st","summary":"Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) - simplywall.st","headline":"Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5SaF94VEIzSjVfQ0EyMWEzR0RmZlNYNXdiOVc2clQ5WEV0dUVVSmZfQWhNa0JYTW9oRmh2dWkxWE5sTmRCTm52bXhjWDc5VkZQRG9v?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"IONS Stock Price, News & Analysis - Stock Titan","headline":"IONS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNa201c0FiNUFXR1dCQnhpenJGR3hWV0tGc1d5OGFKSlpnTWR6elRXdGw3NlJkaWJPX016SHF6RGxvSFpPU3lJX3doTlY5ZlhEZmowOGNvVElQSndlcHFQODNqLS1Kb2RFeFdzWVJyakE1c0hxMFdEYnI2VHY3VUZRWWM1ZUpIT1BqcnBOT3diS0tqV0l2WXZaY2xHRVl2aVltTWNNNTJOMVpQX2JjRDJmVHFsOUpGQkZLdTRkbmdDdmJCVzYtclh3Y1ZoaTcyZGJEc3NaTm1yVGc?oc=5","date":"2025-03-11","type":"deal","source":"Business Wire","summary":"Ionis and Ono announce global license agreement for sapablursen in polycythemia vera - Business Wire","headline":"Ionis and Ono announce global license agreement for sapablursen in polycythemia vera","sentiment":"neutral"}],"patents":[{"drugName":"Tegsedi","drugSlug":"inotersen","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Tegsrolin","drugSlug":"ionis-ttr-l01","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":14,"phaseCounts":{"phase_3":2,"phase_2":7,"phase_1":5},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Alnylam Pharmaceuticals","Biogen","Pfizer"],"therapeuticFocus":["RNA Therapeutics","Neurodegenerative Diseases","Rare Genetic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":203330000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":203330000,"period":"2025-12-31"},{"value":226577000,"period":"2024-12-31"},{"value":226577000,"period":"2024-12-31"},{"value":324505000,"period":"2023-12-31"},{"value":324505000,"period":"2023-12-31"}],"grossProfit":927802000,"grossProfitHistory":[{"period":"2025-12-31","value":927802000},{"period":"2024-12-31","value":693923000},{"period":"2023-12-31","value":778514000},{"period":"2022-12-31","value":573251000}],"rdSpend":915619000,"rdSpendHistory":[{"period":"2025-12-31","value":915619000},{"period":"2024-12-31","value":901530000},{"period":"2023-12-31","value":899625000},{"period":"2022-12-31","value":833147000}],"sgaSpend":393900000,"operatingIncome":-381717000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-381717000},{"period":"2024-12-31","value":-475107000},{"period":"2023-12-31","value":-353730000},{"period":"2022-12-31","value":-410191000}],"netIncome":-381387000,"netIncomeHistory":[{"period":"2025-12-31","value":-381387000},{"period":"2024-12-31","value":-453897000},{"period":"2023-12-31","value":-366286000},{"period":"2022-12-31","value":-269722000}],"eps":-2.38,"epsHistory":[{"period":"2025-12-31","value":-2.38},{"period":"2024-12-31","value":-3.04},{"period":"2023-12-31","value":-2.56},{"period":"2022-12-31","value":-1.9}],"cash":372260000,"cashHistory":[{"period":"2025-12-31","value":372260000},{"period":"2024-12-31","value":242077000},{"period":"2023-12-31","value":399266000},{"period":"2022-12-31","value":276472000}],"totalAssets":3523836000,"totalLiabilities":3034747000,"totalDebt":2064512000,"equity":489089000,"operatingCashflow":-268583000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-268583000},{"period":"2024-12-31","value":-500947000},{"period":"2023-12-31","value":-307513000},{"period":"2022-12-31","value":-274370000}],"capex":-57084000,"capexHistory":[{"period":"2025-12-31","value":-57084000},{"period":"2024-12-31","value":-50341000},{"period":"2023-12-31","value":-27989000},{"period":"2022-12-31","value":-20099000}],"freeCashflow":-325667000,"dividendsPaid":null,"buybacks":0,"employees":1402,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":150400000,"ebit":-71973000,"ebitda":-64526000,"period":"2026-03-31","revenue":246091000,"epsBasic":-0.56,"netIncome":-92528000,"rdExpense":210173000,"epsDiluted":-0.56,"grossProfit":243091000,"operatingIncome":-117482000},{"sga":130200000,"ebit":-206856000,"ebitda":-199515000,"period":"2025-12-31","revenue":203330000,"epsBasic":-1.41,"netIncome":-229394000,"rdExpense":279646000,"epsDiluted":-1.41,"grossProfit":195373000,"operatingIncome":-214473000},{"sga":96800000,"ebit":-107841000,"ebitda":-103339000,"period":"2025-09-30","revenue":156719000,"epsBasic":-0.8,"netIncome":-128606000,"rdExpense":217754000,"epsDiluted":-0.8,"grossProfit":154381000,"operatingIncome":-160173000},{"sga":90600000,"ebit":144779000,"ebitda":150233000,"period":"2025-06-30","revenue":452049000,"epsBasic":0.78,"netIncome":123551000,"rdExpense":217460000,"epsDiluted":0.7,"grossProfit":447898000,"operatingIncome":139838000},{"sga":76300000,"ebit":-125400000,"ebitda":-120003000,"period":"2025-03-31","revenue":131612000,"epsBasic":-0.93,"netIncome":-146938000,"rdExpense":200759000,"epsDiluted":-0.93,"grossProfit":130112000,"operatingIncome":-146947000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":75.71,"previousClose":77.6,"fiftyTwoWeekHigh":86.74,"fiftyTwoWeekLow":32,"fiftyTwoWeekRange":"32.0 - 86.74","fiftyDayAverage":74.34,"twoHundredDayAverage":71.06,"beta":0.38,"enterpriseValue":13456955392,"forwardPE":-122.1,"priceToBook":25.56,"priceToSales":11.82,"enterpriseToRevenue":12.72,"enterpriseToEbitda":-39.74,"pegRatio":0,"ebitda":-338648992,"ebitdaMargin":-32,"freeCashflow":-807796352,"operatingCashflow":-910627008,"totalDebt":2609644032,"debtToEquity":531,"currentRatio":4.1,"returnOnAssets":-7,"returnOnEquity":-67.6,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":23,"targetMeanPrice":100.74,"targetHighPrice":130,"targetLowPrice":47,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.6,"institutionHeldPercent":109.1,"sharesOutstanding":165262556,"floatShares":163980119,"sharesShort":16279706,"shortRatio":9.12,"shortPercentOfFloat":9.9,"epsTrailing":-2.01,"epsForward":-0.62,"revenuePerShare":6.55,"bookValue":2.96,"officers":[{"age":64,"name":"Dr. Brett P. Monia Ph.D.","title":"Founder, CEO & Director"},{"age":63,"name":"Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.","title":"Executive VP of Finance & CFO"},{"age":51,"name":"Mr. Patrick R. O'Neil Esq.","title":"Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary"},{"age":59,"name":"Dr. Eric E. Swayze Ph.D.","title":"Executive Vice President of Research"},{"age":59,"name":"Mr. Brian  Birchler","title":"Executive Vice President of Corporate & Development Operations"},{"age":67,"name":"Dr. Richard S. Geary Ph.D.","title":"Strategic Consultant"},{"age":52,"name":"Dr. Eugene  Schneider M.D.","title":"Executive VP, Chief Clinical Development & Operations Officer"},{"age":null,"name":"Mr. Darren  Gonzales","title":"Chief Accounting Officer & Senior VP"}],"industry":"Biotechnology","irWebsite":"http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome","website":"https://www.ionis.com","phone":"760 931 9200"}}